SCHEMBL497836

SCHEMBL497836

C[C]c1ccc(OC)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA7 P43166 2/20 0.61
CA9 Q16790 2/20 0.61
CA12 O43570 1/20 0.61
CA14 Q9ULX7 1/20 0.61
APP P05067 2/20 0.60
TDP1 Q9NUW8 3/20 0.55
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 2/20 0.52
CYP3A4 P08684 1/20 0.52
ACHE P22303 1/20 0.50
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4082593 0.80 CA1 (0.65) CA1CA2CA7CA9CA12
SCHEMBL674764 0.80 APP (0.77) CA1CA2CA7CA9CA12
SCHEMBL10300057 0.80 APP (0.77) CA1CA2CA7CA9CA12
SCHEMBL5244673 0.79 APP (0.68) CA1CA2CA7CA9CA12
SCHEMBL2187089 0.78 APP (0.39) APPALDH1A1MAPT
1,4-Dimethoxybenzene SCHEMBL21802643 0.78 CA1 (1.00) CA1CA2CA7CA9CA12
1,4-Dimethoxybenzene SCHEMBL8489 0.78 CA1 (1.00) CA1CA2CA7CA9CA12
SCHEMBL9715639 0.78 APP (0.74) CA1CA2CA7CA9CA12
SCHEMBL9333443 0.77 APP (0.72) CA1CA2CA7CA9CA12
SCHEMBL1099 0.76 CA1 (0.58) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7556844-B2 Radiation curable photochromic inks XEROX CORPORATION (US) 2009-07-07 US claimed
US-20070211110-A1 RADIATION CURABLE PHOTOCHROMIC INKS XEROX CORPORATION (US) 2007-09-13 US claimed
WO-2024135721-A1 METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME 田辺三菱製薬株式会社 2024-06-27 WO disclosed
EP-3160475-B1 SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES TO TREAT FILOVIRIDAE INFECTIONS JANSSEN PHARMACEUTICALS INC (US) 2024-01-03 EP disclosed
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 EP disclosed
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-06-01 US disclosed
US-11590155-B2 Substituted nucleosides, nucleotides and analogs thereof JANSSEN PHARMACEUTICA NV (BE) 2023-02-28 US disclosed
US-11485753-B2 Substituted nucleosides, nucleotides and analogs thereof JANSSEN PHARMACEUTICA NV (BE) 2022-11-01 US disclosed
EP-3912984-A1 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV Janssen BioPharma, Inc. (US) 2021-11-24 EP disclosed
US-20210317490-A1 ANTICANCER COMPOUNDS PHARMA MAR, S.A., (ES) 2021-10-14 US disclosed
US-5693771-A REACTING PROTECTED PYRAN COMPOUND WITH PHOSPHITE AND HETEROCYCLIC BASE GILEAD SCIENCES, INC. (US) 1997-12-02 US disclosed
EP-0807118-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1997-11-19 EP disclosed
EP-0789695-A2 THIEPANE COMPOUNDS INHIBITING AND DETECTING HIV PROTEASE GILEAD SCIENCES, INC. (US) 1997-08-20 EP disclosed
US-5659023-A HETEROCYCLIC FURANOSYL OR PYRANOSYL PHOSPHONATE; IMMUNOGENS, OLIGONUCLEOTIDES, ANTIINFECTIVES, ANTIINFLAMMATORY AGENTS GILEAD SCIENCES, INC. (US) 1997-08-19 US disclosed
EP-0759917-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1997-03-05 EP disclosed
WO-1996026933-A9 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES 1996-11-28 WO disclosed
WO-1996026933-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1996-09-06 WO disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 WO disclosed
WO-1996014314-A2 THIEPANE COMPOUNDS INHIBITING AND DETECTING HIV PROTEASE GILEAD SCIENCES, INC. (US) 1996-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485753-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C2 CA1 4884/4885CA2 4882/4885CA7 4836/4885
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 CA1 4884/4885CA2 4882/4885CA7 4836/4885
US-20210317490-A1 ANTICANCER COMPOUNDS SLC75A1, SLC15A1, LCT CA1 3586/4885CA2 2398/4885CA7 1621/4885
US-11590155-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, NUDT1, NT5C3B CA1 4869/4885CA2 4864/4885CA7 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.